Competing Pharma Change of Control means a Change of Control in which a company or group of companies acting in concert (a) for which the collective worldwide sales of ethical pharmaceutical products in the Calendar Year that preceded the Change of Control were one billion United States dollars (US$1,000,000,000) or more, or (b) which has a research, development or commercialization program for any preparation or product that may be used for the treatment of an Initial Indication, or any other preparation or product that is reasonably considered to be competitive with any Cue Biologic, Compound or Product, is the acquirer (by asset purchase, merger, consolidation, reorganization or otherwise) as part of such Change of Control.
Competing Pharma Change of Control means a Change of Control of NGM (or any Affiliate of NGM that Controls any of the NGM IP or any NP201 IP or other assets required for the Collaboration (including Collaboration Technology)) in which a company or group of companies acting in concert, for whom collective worldwide sales of [*] in the Calendar Year that preceded the Change of Control were [*], is the Acquiror as part of such Change of Control.
Competing Pharma Change of Control means a Change of Control in which a company or group of companies acting in concert (a) for whom aggregate worldwide sales of [ * ] in the Calendar Year that preceded the Change of Control were [ * ], or (b) [ * ].
Examples of Competing Pharma Change of Control in a sentence
If the Change of Control that is described in the Zymeworks Change of Control Notice results in a Competing Pharma Change of Control then, Zymeworks shall notify Merck in writing of the effective date of such Change of Control and following the effective date of such Change of Control, the rights granted herein remain in effect.
In the event of a Competing Pharma Change of Control involving Xxxxx, Merck’s obligation to provide reports pursuant to this sub-paragraph (f) shall be limited to providing a report of the Royalty due on a worldwide basis.
Without limiting the foregoing, in the event that there is a Company Change of Control that is a Competing Pharma Change of Control, then Cocrystal shall provide written notice to Merck at least [*] prior to the completion of such Change of Control and [*].
When developing an adverse event reporting database it is essential to recruit user interface designers who are able to assist frontline staff through acceptance testing to accurately enter information about complex critical incidents into the database (Johnson 2003).
More Definitions of Competing Pharma Change of Control
Competing Pharma Change of Control means a Change of Control involving a Person or group of Persons acting in concert (a) with annual worldwide sales of human pharmaceutical, Vaccine and/or biological products greater than [***], (b) that sell human pharmaceutical, Vaccine and/or biological products where such Person or group of Persons have a market capitalization greater [***]) or (c) having an active clinical development or commercialization program for any Vaccine within a Field.
Competing Pharma Change of Control means a change of control in which a company or group of companies acting in concert to acquire the Company as of immediately prior to such change of control of the Company [***].
Competing Pharma Change of Control means a Change of Control involving a Competitive Entity.
Competing Pharma Change of Control means a Change of Control in which the acquirer is a company or group of companies acting in concert (a) for whom collective worldwide sales of pharmaceutical products in the Calendar Year that preceded the year in which the Change of Control was consummated were [ * ] United States dollars [ * ] or more, or (b) who have an active clinical development or commercialization program for any pharmaceutical or diagnostic product intended to treat, prevent and/or diagnose a Major Indication.
Competing Pharma Change of Control means a Change of Control in which a company or group of companies acting in concert (other than the Parties and their respective Affiliates) (a) for which the collective worldwide sales of ethical pharmaceutical products in the Calendar Year that preceded the Change of Control were [* * *] United States dollars (US$[* * *]) or more, or (b) which has a research, development or commercialization program for a product which would compete with a Product, is the acquirer (by asset or business purchase) or becomes the controlling equity holder of the surviving entity (as a result of a merger, consolidation or reorganization), as the case may be, as part of or as a result of such Change of Control. Notwithstanding anything to the contrary in this Agreement, in the event that Biogen Idec Therapeutics Inc. or any of its Affiliates (as defined in the Joint Venture Agreement dated December 6, 2011 between Samsung BioLogics Co., Ltd. and Biogen Idec Therapeutics Inc.) comes to collectively own, control or hold fifty percent (50%) or more of the total issued and outstanding voting securities or other ownership interests of Samsung, whether directly or indirectly (the “Biogen Change of Control of Samsung”), and at such time Biogen Idec Therapeutics Inc. and/or any of such Affiliates (individually or collectively) meet the criteria set forth in (a) or (b) hereinabove, the Biogen Change of Control of Samsung shall constitute a Competing Pharma Change of Control.
Competing Pharma Change of Control means a Change of Control in which a company or group of companies acting in concert (collectively a "COMPETING PHARMA") (a) for whom collective worldwide sales of ethical pharmaceutical products in the Calendar Year that preceded the Change of Control were [***], or (b) have a research, development or commercialization program for a [***], is the acquirer (by asset purchase, merger, consolidation, reorganization or otherwise) as part of such Change of Control.
Competing Pharma Change of Control shall have the meaning ascribed to it in Section 13.2.2 hereof.